Fulcrum Therapeutics discontinued development of its sickle cell disease candidate after concerns raised by the FDA, triggering a corporate restructure that eliminated most roles. The company filed details with the SEC indicating 48 of 57 employees would be headed out the door, with remaining capacity reduced to a small team as Fulcrum seeks strategic alternatives following the program halt.